Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

Core Insights - Arch Biopartners Inc. has received approval from the Fraser Health Research Ethics Board for the Royal Columbian Hospital to participate in the Phase II trial of LSALT peptide aimed at preventing and treating cardiac surgery-associated acute kidney injury [1][2] - The company is actively expanding its clinical trial sites, with Royal Columbian Hospital being the eighth site globally and the fourth in Canada to recruit patients [2][3] - Arch Biopartners has completed the acquisition of Lipdro Therapeutics Inc., which includes a CKD drug candidate platform, in exchange for 250,000 common shares and a royalty on future net sales [4] - The Board of Directors has granted 750,000 stock options to directors and officers, exercisable at $1.70 per share for ten years, as part of their remuneration [5] Company Developments - The ongoing Phase II trial for LSALT peptide is part of a broader initiative to address acute kidney injury, with additional sites being evaluated in Canada and the U.S. [3][9] - The acquisition of Lipdro Therapeutics enhances the company's capabilities in developing treatments for chronic kidney disease, targeting IL-32 [4] - Arch Biopartners is focused on developing novel drugs for both acute and chronic kidney diseases, addressing significant unmet medical needs globally [6]